^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    JAK2 R683G

    i
    Other names: JTK10, THCYT3, JAK2, Janus Kinase 2, Tyrosine-Protein Kinase JAK2, JAK-2
    Entrez ID:
    3717
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    almost3years
    Prognostic significance of CRLF2 overexpression and JAK2 mutation in Egyptian pediatric patients with B-precursor acute lymphoblastic leukemia. (PubMed, Clin Lymphoma Myeloma Leuk)
    CRLF2 expression was significantly higher in Egyptian precursor B-ALL pediatric patients. CRLF2 overexpression was associated with a number of unfavorable prognostic factors with high tumor load, but was not an adverse independent parameter in pediatric BCP-ALL patients. Some patients with CRLF2 overexpression display JAK2 mutation, which may benefit from targeted therapy by kinase inhibitors.
    Clinical • Journal
    |
    JAK2 (Janus kinase 2) • CRLF2 (Cytokine Receptor Like Factor 2)
    |
    JAK2 mutation • CRLF2 mutation • JAK2 R683G • JAK2 overexpression
    over3years
    A typical acute lymphoblastic leukemia JAK2 variant, R683G, causes an aggressive form of familial thrombocytosis when germline. (PubMed, Leukemia)
    No abstract available
    Journal
    |
    JAK2 (Janus kinase 2)
    |
    JAK2 R683G